Crohn's disease: A review of treatment options and current research

被引:45
作者
Bandzar, Sean [1 ]
Gupta, Shabnam [2 ]
Platt, Manu O. [3 ]
机构
[1] Georgia Regents Univ, Med Coll Georgia, Augusta, GA 30912 USA
[2] Emory Univ, Sch Med, Atlanta, GA USA
[3] Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA
关键词
Crohn's disease; TNF-alpha blocker; HUMAN GROWTH-HORMONE; ANTI-CD3 ANTIBODY VISILIZUMAB; RHEUMATOID-ARTHRITIS; NECROSIS-FACTOR; MULTIPLE-SCLEROSIS; CERTOLIZUMAB PEGOL; MONOCLONAL-ANTIBODY; ULCERATIVE-COLITIS; IMMUNE-RESPONSES; BINDING PROTEIN;
D O I
10.1016/j.cellimm.2013.11.003
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Crohn's disease is an autoimmune disorder that affects nearly 1.4 million Americans. The etiology of Crohn's disease is not completely understood, however, research has suggested a genetic link. There is currently no known cure for Crohn's disease and, as a result, most government-funded research is being conducted to increase the quality of life of afflicted patients (i.e. reducing chronic inflammation and alleviating growth impairment in pediatric patients). A number of treatment options are available including an alpha-4 integrin inhibitor and several TNF-alpha inhibitors. Furthermore, research is being conducted on several alternative treatment options to help understand exactly which cellular mechanisms (i.e. inducing apoptosis in leukocytes) are required for clinical efficacy. This review seeks to chronicle the current available treatment options for patients affected by Crohn's disease to aid in understanding potential cellular mechanistic requirements for an efficacious drug, and shed light on potential options for future treatment. Crown Copyright (C) 2013 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:45 / 52
页数:8
相关论文
共 87 条
  • [1] [Anonymous], 2013, JOHNS JOHNS PHARM RE
  • [2] [Anonymous], 2010, CROHNS COLITIS FDN A
  • [3] [Anonymous], 2011, DRUG ENF ADM HUM GRO
  • [4] In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease
    Autschbach, F
    Braunstein, J
    Helmke, B
    Zuna, I
    Schürmann, G
    Niemir, ZI
    Wallich, R
    Otto, HF
    Meuer, SC
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (01) : 121 - 130
  • [5] Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease
    Bassaganya-Riera, Josep
    Hontecillas, Raquel
    Horne, William T.
    Sandridge, Mikki
    Herfarth, Hans H.
    Bloomfeld, Richard
    Isaacs, Kim L.
    [J]. CLINICAL NUTRITION, 2012, 31 (05) : 721 - 727
  • [6] Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Visilizumab (HuM291) in Crohn's Disease
    Baumgart, Daniel C.
    Lowder, James N.
    Targan, Stephan R.
    Sandborn, Wlliiam J.
    Frankel, Matthew B.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (04) : 868 - 876
  • [7] CHRONIC INTERMITTENT ELEMENTAL DIET IMPROVES GROWTH FAILURE IN CHILDREN WITH CROHNS-DISEASE
    BELLI, DC
    SEIDMAN, E
    BOUTHILLIER, L
    WEBER, AM
    ROY, CC
    PLETINCX, M
    BEAULIEU, M
    MORIN, CL
    [J]. GASTROENTEROLOGY, 1988, 94 (03) : 603 - 610
  • [8] Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: A pilot study
    Calenda, KA
    Schornagel, IL
    Sadeghi-Nejad, A
    Grand, RJ
    [J]. INFLAMMATORY BOWEL DISEASES, 2005, 11 (05) : 435 - 441
  • [9] Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease
    Carol, Monica
    Borruel, Natalia
    Antolin, Maria
    Llopis, Marta
    Casellas, Francesc
    Guarner, Francisco
    Malagelada, Juan-R.
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 79 (05) : 917 - 922
  • [10] CHAN PY, 1993, J BIOL CHEM, V268, P24655